Logo Image
News
Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Watch
Expert ConversationsShows & PodcastNews & Analysis
Conferences
Conference CoverageConference Listing
Publications
More
CME/CE
Continuing Education
Resources
Case-Based Digest Rx Road MapEventsAdvanced Practice Corner
Partners

Subscribe

  • News
  • Watch
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Partners
  • Brain Cancer
  • Breast Cancer
    • Metastatic Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Gastric Cancers
  • Genitourinary Cancer
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Cervical Cancer
    • Ovarian Cancer
  • Head and Neck Cancers
  • Hematology
    • Leukemia
    • Graft-Vs-Host Disease
    • Myeloproliferative Neoplasms
    • Multiple Myeloma
    • Lymphoma
  • Lung Cancer
  • Pediatric Cancer
  • Sarcomas
  • Skin Cancer
    • Melanoma
Advertisement

Paula Anastasia, RN, MN, AOCN

Advertisement

Articles by Paula Anastasia, RN, MN, AOCN

Paula Anastasia on PARP Inhibitor Ineligibility Factors for Women With Ovarian Cancer

Paula Anastasia on PARP Inhibitor Ineligibility Factors for Women With Ovarian Cancer

ByPaula Anastasia, RN, MN, AOCN
August 8th 2022

Paula Anastasia, RN, MN, AOCN, highlights circumstances in which patients may not be eligible to receive benefit with a PARP inhibitor.

Advertisement

Latest Updated Articles

  • Paula Anastasia on PARP Inhibitor Ineligibility Factors for Women With Ovarian Cancer
    Paula Anastasia on PARP Inhibitor Ineligibility Factors for Women With Ovarian Cancer

    August 8th 2022



Advertisement
Advertisement

Trending on Oncology Nursing News

1

Automated Breast Ultrasound Tied to Fewer False-Positives in Dense Breasts

2

Delaying BSO to Age 50 Leaves BRCA1 Carriers With 24% Ovarian Cancer Risk

3

FDA Expands Anktiva Approval to Papillary-Only BCG-Unresponsive NMIBC

4

Anktiva for Papillary NMIBC: What Nurses Need to Know About the Regimen

5

GLP-1s After Breast Cancer: What Nurses Should Ask Survivors

  • About Us
  • Editorial Board
  • Contact Us
  • CancerNetwork.com
  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Advertise
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us